Search Results

You are looking at 251 - 260 of 578 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Colon Cancer, Version 2.2018

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

tolerated in 30 patients, with dose-limiting toxicities in 5 patients (cetuximab infusion reaction, n=2; grade 2 retinopathy, n=2; grade 2 decreased ejection fraction, n=1). Of the 30 patients, 19 (63%) experienced a grade 3 or 4 AE, including fatigue (grade

Full access

Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults

Kah Poh Loh, Vivian Lam, Katey Webber, Simran Padam, Mina S. Sedrak, Vivek Musinipally, Madison Grogan, Carolyn J. Presley, Janice Grandi, Chandrika Sanapala, Daniel A. Castillo, Grace DiGiovanni, Supriya G. Mohile, Louise C. Walter, and Melisa L. Wong

Jong N , Candel MJ , Schouten HC , Course of the fatigue dimension “activity level” and the interference of fatigue with daily living activities for patients with breast cancer receiving adjuvant chemotherapy . Cancer Nurs 2006 ; 29 : E1

Full access

Abstracts From the NCCN 2022 Annual Conference

fractions twice a week. Dose escalation followed a 3 + 3 design. The DLT was defined as grade 3 or 4 nonhematologic toxicity, excluding nausea, vomiting and alopecia, decreased appetite and fatigue, or grade 4 hematologic toxicity. Results : This study was

Full access

Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer

Nicolas Batty, Naveen Yarlagadda, and Roberto Pili

a 2 weeks on, 2 weeks off schedule, and prednisone was continued at 5 mg orally daily. 3 While on therapy, the patient denied any fatigue and reported only intermittent right leg pain from metastases. Repeat PSA level at 6 months of cyclophosphamide

Full access

Treatment Disparities Faced by Undocumented Workers From Low- and Middle-Income Countries in the United States With Hematologic Malignancies

Sara E. Nunnery, Andrew E. Fintel, W. Clay Jackson, Jason C. Chandler, Michael O. Ugwueke, and Mike G. Martin

support because of his undocumented immigration status and lack of insurance. In another example, a 40-year-old Hispanic man presented to the hospital with generalized fatigue, weakness, and weight loss. He was found to have a WBC count of 205,000 cells

Full access

Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib

Vinod Ravi, Eric M. Sanford, Wei-Lien Wang, Jeffrey S. Ross, Naveen Ramesh, Andrew Futreal, Shreyaskumar Patel, Phillip J. Stephens, Vincent A. Miller, and Siraj M. Ali

-matched normal controls. additional treatment due to fatigue that was disabling. He was then transitioned to hospice care. Pazopanib treatment was successful in producing a partial response that was sustained for 6 months. The durability of the response is

Full access

Updates to the Management of Chronic Lymphocytic Leukemia

William G. Wierda

. Indications for treatment include progressive symptoms such as night sweats, fatigue, weight loss, and anemia, which have not changed over the years. “The 1996 NCI guidelines are consistent with the 2008 IWCLL guidelines in regard to when to start treatment

Full access

Emerging Treatment Options for B-Cell Lymphomas

Andrew D. Zelenetz

hint that the activity is somewhat greater,” he said. He added that these are very small numbers and larger confirmatory studies are needed to validate these findings. The most common side effects were fatigue, pneumonitis, and pruritus. “The safety

Full access

Targeted/Emerging Therapies for Metastatic Non–Small Cell Lung Cancer

Leora Horn

those with previously treated lung cancer with the ALK rearrangement. 10 In addition, “There was an improvement in many quality-of-life scales, including dyspnea, cough, fatigue, and pain control,” Dr. Horn noted. Ceritinib has been approved for the

Full access

Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera

Radhika Gangaraju, Soo J. Kim, Jing-Fei Dong, Sabina Swierczek, and Josef T. Prchal

sedimentation rate were normal at that time. She was on oral contraceptives, which were thought to have contributed to the stroke, and her high blood counts were considered to be reactive. She developed significant fatigue and depression after the stroke